HUMA Stock Analysis: Buy, Sell, or Hold?
HUMA - Humacyte, Inc. Common Stock
$0.71
0.04 (5.56%)
▲
5d:
+14.52%
30d:
-48.92%
90d:
+19.95%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When HUMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HUMA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: HUMA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: HUMA is currently trading at $0.71, which is considered oversold relative to its 30-day fair value range of $0.78 to $1.34.
Technical Outlook: Technically, HUMA is in a strong downtrend. The price is currently testing key support at $1.10. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 5.6% recently.
Market Sentiment: HUMA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $2.05 (+188.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HUMA is in a strong downtrend. The price is currently testing key support at $1.10. A bounce from this level would confirm strength, while a break below could signal further downside. The stock is showing strong short-term momentum, up 5.6% recently.
Market Sentiment: HUMA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $2.05 (+188.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.78 -
$1.34
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.6%)
- BULLISH: Trading 188.7% below Wall St target ($2.05)
Trading Range Analysis
30-Day Trading Range
$0.78 -
$1.34
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.10
Resistance Level
$1.53
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.96
Wall Street Target
$2.05
(+188.7%)
Revenue Growth (YoY)
-4.3%
Share & Embed Analysis
Last updated: July 02, 2026 10:45 PM ET
Data refreshes hourly during market hours. Next update: 11:45 PM
Data refreshes hourly during market hours. Next update: 11:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HUMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
